An important aspect of this study is that blood and tumor sequencing is provided free of charge and the results are communicated to patients and their providers within two months of enrollment. This information may allow you to make personalized treatment decisions for future therapy. Further, patients can follow with their local oncologist, and on study return to Mayo is required only at the restaging intervals. As patients need to undergo a baseline research biopsy, we wish to identify potential participants as soon as possible to avoid the need for re-biopsy and repeat scans when possible (given that many will have staging scans and a baseline, standard-of-care biopsy as part of their workup). Further, if you are referring an interested patient, we would also request that they not be commenced on endocrine therapy or palbociclib in advance of their visit, as this would render them ineligible.

Enrollment Updates:
- 49 patients have been accrued to date across all three Mayo Clinic sites.

Approved Patient Video
To assist with patient information when introducing this study, you have access to a video in which Dr. O'Sullivan explains the trial in lay language.
External YouTube: PROMISE YouTube LINK

Why is the PROMISE study important? Genome-guided care has demonstrated value in precision cancer medicine. The majority of cancer genomics studies focus on only a subset of known genes to determine the right drug for a patient. However, a comprehensive clinical and genomic evaluation of a patient by the interdisciplinary team of scientists and clinicians is critical to address drug-resistant cancers. Our PROMISE study is unique in bringing a team of experts together to generate and analyze comprehensive genomics data from each patient; millions of data points thus analyzed through our predictive analytics workflows are expected to inform biomarkers and molecular mediators of drug resistance in that individual patient. The findings of this personalized genomic analysis will be transferred to our oncologists to facilitate the identification of better treatment options for the patient. The outcomes of this study are expected to positively impact the treatment of our current patients and also lay foundations for identifying effective interventions for our future patients.
What I enjoy doing in my spare time? I like spending time with my family and friends, listening to music, dancing, and traveling. Learning anything new is fun for me, so in my spare time, I also like learning about new analytical methods.
Protocol Questions: Ciara O'Sullivan, MB, BCh, Co-Chair: Contact info is below.

References:
PROMISE Chairs: